Skip to Content
Merck
All Photos(2)

Documents

93813

Supelco

Cyclophosphamide monohydrate

analytical standard

Synonym(s):

2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide, Cytoxan

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C7H15Cl2N2O2P · H2O
CAS Number:
6055-19-2
Molecular Weight:
279.10
Beilstein:
4678992
EC Number:
200-015-4
MDL number:
MFCD00149395
UNSPSC Code:
41116107
PubChem Substance ID:
329770272
NACRES:
NA.24

grade

analytical standard

Quality Level

100

Assay

≥98.0% (HPLC)

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

impurities

6.45% water (theory, monohydrate)

mp

47-52 °C
49-51 °C (lit.)

application(s)

forensics and toxicology
veterinary

format

neat

storage temp.

2-8°C

SMILES string

[H]O[H].ClCCN(CCCl)P1(=O)NCCCO1

InChI

1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2

InChI key

PWOQRKCAHTVFLB-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

Cyclophosphamide is a cytotoxic nitrogen mustard derivative widely used in cancer chemotherapy. It cross-links DNA, causes strand breakage, and induces mutations. Its clinical activity is associated with a decrease in aldehyde dehydrogenase 1 (ALDH1) activity.

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301,H340,H350,H360FD

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1B - Muta. 1B - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCJ5425
BCCG4445
BCCB7788
BCBT1588
BCBM8984V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Fludarabine phosphate

Sigma-Aldrich

F9813

Fludarabine phosphate

Azathioprine ≥98%

Sigma-Aldrich

A4638

Azathioprine

Ji-Young Lee et al.
Chemosphere, 268, 128817-128817 (2020-11-10)
Cyclophosphamide (CP) is a widely used anticancer drug and an immunosuppressant. Since CP is nonbiodegradable, it is hardly removed by the conventional wastewater treatment processes, resulting in continuous detection in surface water. In this study, the degradation of CP during
Feng Zhao et al.
Pharmaceutical biology, 52(7), 797-803 (2014-01-08)
The in vitro and in vivo antitumor activities of ardisiphenol D, a natural product isolated from the roots of Ardisa brevicaulis Diels (Myrsinaceae), have been studied. Previously, we have isolated and identified some chemical constituents from this plant. Furthermore, these
Masahiro Murakami-Nakayama et al.
Journal of pharmacological sciences, 127(2), 223-228 (2015-03-03)
Cav3.2 T-type Ca(2+) channels targeted by H2S, a gasotransmitter, participate in cyclophosphamide-induced cystitis and bladder pain. Given that zinc selectively inhibits Cav3.2 among T-channel isoforms and also exhibits antioxidant activity, we examined whether polaprezinc (zinc-l-carnosine), a medicine for peptic ulcer
Yue Jia et al.
Apoptosis : an international journal on programmed cell death, 20(4), 551-561 (2015-02-11)
Human (HN) prevents stress-induced apoptosis in many cells/tissues. In this study we showed that HN ameliorated chemotherapy [cyclophosphamide (CP) and Doxorubicin (DOX)]-induced male germ cell apoptosis both ex vivo in seminiferous tubule cultures and in vivo in the testis. HN
Lamprini Skriapa et al.
Journal of neuroimmunology, 276(1-2), 150-158 (2014-09-30)
Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service